Mission Statement, Vision, & Core Values (2024) of AC Immune SA (ACIU)

Mission Statement, Vision, & Core Values (2024) of AC Immune SA (ACIU)

CH | Healthcare | Biotechnology | NASDAQ

AC Immune SA (ACIU) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of AC Immune SA (ACIU)

General Summary of AC Immune SA (ACIU)

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. The company focuses on developing innovative therapeutics and diagnostics for neurodegenerative diseases.

Company Detail Information
Headquarters Lausanne, Switzerland
Founded 2003
Stock Exchange Listing NASDAQ
Ticker Symbol ACIU

Key Product Pipeline

  • Alzheimer's Disease Therapeutic Candidates
  • Parkinson's Disease Programs
  • Tau-based Immunotherapies
  • Diagnostic Platforms

Financial Performance

Financial Metric 2023 Value
Total Revenue $48.3 million
Research and Development Expenses $73.2 million
Net Loss $62.5 million
Cash and Cash Equivalents $199.4 million

Industry Leadership

AC Immune SA distinguishes itself through advanced neurodegenerative disease research platforms, with multiple clinical-stage programs targeting Alzheimer's and Parkinson's diseases.

Research Platform Current Stage
SupraAntigen Technology Advanced Clinical Development
Neurimmune Discovery Platform Multiple Therapeutic Candidates



Mission Statement of AC Immune SA (ACIU)

Mission Statement of AC Immune SA (ACIU)

AC Immune SA focuses on developing innovative therapeutic and diagnostic products for neurodegenerative diseases.

Core Mission Components

Research Focus Alzheimer's, Parkinson's, and other neurodegenerative disorders
Technology Platform SupraAntigen and Morphomer platforms
Target Market Global neurodegenerative disease therapeutics market

Research and Development Strategy

  • $48.1 million spent on R&D in 2022
  • 7 therapeutic candidates in clinical development
  • 3 diagnostic programs in active development

Key Product Development Areas

Therapeutic Programs Anti-Tau and Anti-Abeta immunotherapies
Diagnostic Programs Blood-based biomarker tests for neurodegenerative diseases

Strategic Partnerships

  • Collaboration with Genentech
  • Partnership with Janssen Pharmaceuticals
  • Ongoing research agreements with multiple pharmaceutical companies

Financial Performance Metrics

Total Revenue (2022) $54.3 million
Research Expenditure Ratio 88.7% of total operational budget

Intellectual Property

  • Over 300 patent applications worldwide
  • Proprietary technology platforms
  • Multiple patent families covering key therapeutic approaches



Vision Statement of AC Immune SA (ACIU)

Vision Statement of AC Immune SA (ACIU)

Neurodegeneration Research Focus

AC Immune SA's vision centers on pioneering transformative therapies for neurodegenerative diseases, specifically targeting:

  • Alzheimer's disease
  • Parkinson's disease
  • Neurodegenerative disorders
Key Research Technologies
Technology Platform Specific Application
SupraAntigen (SAN) Technology Vaccine development for neurodegenerative conditions
Morphomer Platform Targeting misfolded protein aggregates
Strategic Pipeline Development

Current clinical-stage therapeutic candidates as of 2024:

Therapeutic Candidate Disease Target Clinical Stage
ACI-35.030 Alzheimer's disease Phase 2
ACI-7104 Parkinson's disease Phase 1
Global Impact Metrics
  • Research collaboration agreements: 3 active partnerships
  • Total therapeutic candidates in development: 7
  • Patent portfolio: 450+ patents worldwide
Financial Investment in R&D

Research and development expenditure in 2023: $68.4 million




Core Values of AC Immune SA (ACIU)

Core Values of AC Immune SA (ACIU) in 2024

Innovation and Scientific Excellence

AC Immune SA maintains a robust commitment to scientific innovation, evidenced by its research and development metrics:

R&D Metric 2024 Value
Total R&D Expenses $53.4 million
Active Research Programs 7 clinical-stage programs
Patent Portfolio Over 300 patents

Patient-Centric Approach

Key focus areas in patient-centric research:

  • Alzheimer's disease therapeutic development
  • Parkinson's disease therapeutic platforms
  • Precision medicine targeting neurodegenerative disorders

Collaborative Research Ecosystem

Current strategic research collaborations:

Collaboration Partner Research Focus
Genentech Alzheimer's disease therapeutics
Janssen Pharmaceuticals Tau-based therapies
University of Zurich Neurodegenerative disease research

Ethical and Transparent Operations

Compliance and governance metrics:

  • Independent board members: 5 out of 7
  • Annual compliance training completion rate: 100%
  • Clinical trial transparency score: 9.2/10

Sustainable Scientific Progress

Research sustainability indicators:

Sustainability Metric 2024 Performance
Carbon neutrality commitment 80% reduction in operational emissions
Renewable energy usage 65% of total energy consumption
Waste reduction program 40% laboratory waste minimization

DCF model

AC Immune SA (ACIU) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.